Detects human CXCL5/ENA‑78 in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant human (rh) GCP-2 is observed and less than 5% cross-reactivity with recombinant mouse (rm) KC, recombinant rat CINC-1, rhGRO alpha, rhGRO gamma and rmGCP-2 is observed.
Polyclonal Goat IgG
E. coli-derived recombinant human CXCL5/ENA-78 Ala37-Asn114 Accession # P42830
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Measured by its ability to neutralize CXCL5/ENA‑78-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR2. The Neutralization Dose (ND50) is typically 0.2-1.0 µg/mL in the presence of 0.03 µg/mL Recombinant Human CXCL5/ENA‑78.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Chemotaxis Induced by CXCL5/ENA‑78 and Neutralization by Human CXCL5/ENA‑78 Antibody.
Recombinant Human CXCL5/ENA‑78 (Catalog # 254‑XB) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL5/ENA‑78 (0.03 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL5/ENA‑78 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF254). The ND50 is typically 0.2-1.0 µg/mL.
CXCL5/ENA‑78 in Human Breast.
CXCL5/ENA‑78 was detected in immersion fixed paraffin-embedded sections of human breast using Goat Anti-Human CXCL5/ENA‑78 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF254) at 5 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
CXCL5/ENA‑78 in Human Breast Cancer Tissue.
CXCL5/ENA‑78 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Goat Anti-Human CXCL5/ENA‑78 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF254) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR-CXC chemokines which are angiostatic (1‑3). Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR+ chemokines, it shares 77% aa sequence identity with CXCL6/GCP-2 and 35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP-2, and CXCL8/IL-8. Inflammatory stimulation upregulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis (3 - 6). Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers (6 - 9). Full length CXCL5 (78 aa) is trimmed at the N-terminus by cathepsin G and chymotrypsin to ENA-74 (74 aa) and ENA-70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5 (10, 11). CXCL5 exerts its effects primarily through interactions with CXCR2 (6, 12). It also binds duffy antigen receptor for chemokines (DARC), which can limit CXCR2-mediated responses (13, 14).
Strieter, R.M. et al. (2005) Cytokine Growth Factor Rev. 16:593.
Balestrieri, M.L. et al. (2008) Cardiovasc. Res. 78:250.
Walz, A.. et al. (1991) J. Exp. Med. 174:1355.
Strieter, R.M. et al. (1992) Immunol. Invest. 21:549.
Koch, A.E. et al. (1994) J. Clin. Invest. 94:1012.
Begley, L.A. et al. (2008) Neoplasia 10:244.
Vandercappellen, J. et al. (2008) Cancer Lett. 267:226.
Arenberg, D.A. et al. (1998) J. Clin. Invest. 102:465.
Miyazaki, H. et al. (2006) Cancer Res. 66:4279.
Wuyts, A. et al. (1999) Eur. J. Biochem. 260:421.
Nufer, O. et al. (1999) Biochemistry 38:636.
Ahuja, S.K. and P.M. Murphy (1996) J. Biol. Chem. 271:20545.
Kashiwazaki, M. et al. (2003) Int. Immunol. 15:1219.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.